• GON SA ATZETI

    Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due…
  • GON SA EZETI-10

    Primary Hypercholesterolaemia: Ezetimibe co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial…
  • NASRIX

    NASRIX is indicated as an adjunct to diet in the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia, and the combination…